Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Basic Research

Subjective and objective measures of late genitourinary morbidity following hypofractionated radiotherapy in men with prostate cancer

Prostate Cancer and Prostatic Diseases volume 13, pages 34–38 (2010)Cite this article

Abstract

To value the late genitourinary (GU) morbidity in men treated with a hypofractionated radiotherapy regimen for prostate cancer. Patients with intermediate risk factors according to D'Amico's criteria were selected. The hypofractionated schedule consisted of 15 fractions of 3.63 Gy delivered three times per week for a total dose of 54.3 Gy. Significant changes in storage-symptoms were not found. A significant transient worsening in the score of late effects of normal tissue late effects normal tissue task force (LENT)-subjective, objective, management, analytic (SOMA) urinary-function domain was observed at 12 months with subsequent improvement at 28 months. The assessment of voiding-symptoms and maximum urinary flow rate (Qmax) showed that no significant difference was measurable at 12 and 28 months. For PVR, a transient increase at 12 months with a subsequent decrease at 28 months was measured. No significant increase in alpha-blockers usage and in the percentage of men with pathological nonintubated uroflowmetry (NIF) was observed at 12 and 28 months. Finally, patients did not perceive any clinical worsening in their quality of life (QoL) as attested by the International Prostate Symptom Score (IPSS)-QoL. Our study seems to suggest that our hypofractionated radiotherapy schedule for the treatment of prostate cancer is safe in terms of late urinary morbidity. Further study will be required to confirm our results.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002; 53: 1097–1105.

    Article  PubMed  Google Scholar 

  2. Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998; 41: 491–500.

    Article  CAS  PubMed  Google Scholar 

  3. Brenner DJ . Towards optimal external beam fractionation for prostate cancer. Int J Radiat Oncol Biol Phys 2000; 48: 315–316.

    Article  CAS  PubMed  Google Scholar 

  4. Brenner DJ, Hall EJ . Fractionation protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999; 43: 1095–1101.

    Article  CAS  PubMed  Google Scholar 

  5. Fowler J, Chappell R, Ritter M . Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 2001; 50: 1021–1031.

    Article  CAS  PubMed  Google Scholar 

  6. Wang JZ, Guerrero M, Li XA . How low is the alpha/beta ratio for the prostate cancer? Int J Radiat Oncol Biol Phys 2003; 55: 194–203.

    Article  PubMed  Google Scholar 

  7. Bentzen SM, Ritter MA . The alpha/beta ratio for prostate cancer: what is it, really? Radiother Oncol. 2005; 76: 1–3.

    Article  PubMed  Google Scholar 

  8. Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A . Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: long term outcomes. Int J Radiat Oncol Biol Phys 2005; 63: 1463–1468.

    Article  PubMed  Google Scholar 

  9. Martin JM, Rosewall T, Bayley A, Bristow R, Chung P, Crook J et al. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys; 2007; 69: 1084–1089.

    Article  PubMed  Google Scholar 

  10. Soete G, Arcangeli S, De Meerleer G, Landoni V, Fonteyne V, Arcangeli G, De Neve W, Storme G et al. Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity. Radiother Oncol; 2006; 80: 78–81.

    Article  PubMed  Google Scholar 

  11. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L et al. Quality of life and satisfaction with outcome among prostate-cancer survivor. N Engl J Med 2008; 358: 1250–1261.

    Article  CAS  PubMed  Google Scholar 

  12. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2005; 292: 821–827.

    Article  Google Scholar 

  13. Michalski JM, Purdy JA, Winter K, Roach III M, Vijayakumar S, Sandler HM et al. Preliminary reports of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Biol Phys 2000; 46: 391–402.

    Article  CAS  Google Scholar 

  14. Diaz A, Roach M, Marquez C, Coleman L, Pickett B, Wolfe JS et al. Indications for and the significance of seminal vesicles irradiation during 3D conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 1994; 30: 323–329.

    Article  CAS  PubMed  Google Scholar 

  15. Coia LR, Minsky BD, John M . Decision trees and management guidelines. Semin Radiat Oncol 1997; 7: 163–181.

    Article  Google Scholar 

  16. Gravina GL, Costa AM, Ronchi P, Galatioto GP, Luana G, Vicentini C. et al. Bladder outlet obstruction index and maximal flow rate during urodynamic study as powerful predictors for the detection of urodynamic obstruction in women. Neurourol Urodyn 2007; 26: 247–253.

    Article  PubMed  Google Scholar 

  17. Ronchi P, Gravina GL, Galatioto GP, Costa AM, Martella O, Vicentini C et al. Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity. Neurourol Urodyn 2009; 28: 52–57.

    Article  PubMed  Google Scholar 

  18. Sand PK, Dmochowski R . Analysis of the standardization of terminology of lower urinary tract dysfunction: report from the Standardisation Sub-Committee of the International Incontinence Society. Neurourol Urodyn 2002; 21: 167.

    Article  Google Scholar 

  19. Johnstone PAS, Gray C, Powel CR . Quality of life in T 1-3N0 prostate cancer patients with radiation therapy with minimum 10-year follow-up. Int J Radiat Oncol Biol Phys 2000; 46: 833–838.

    Article  CAS  PubMed  Google Scholar 

  20. Brenner DJ . Fractionation late rectal toxicity. Int J Radiat Oncol Biol Phys 2004; 60: 1013–1015.

    Article  PubMed  Google Scholar 

  21. Beekman M, Merrick GS, Butler WM, Allner KE, Allen ZA, Galbreath RW et al. Selecting patients with pre-treatment postvoid residual urine volume less than 100 ml may favourably influence brachytherapy-related urinary morbidity. Urology 2005; 66: 1266–1270.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Experimental Medicine, Division of Radiotherapy, University of L'Aquila, L'Aquila, Italy

    V Tombolini, M Di Genesio Pagliuca & G L Gravina

  2. Division of Radiotherapy, San Salvatore Hospital, L'Aquila, Italy

    M Di Staso, P Bonfili & S Buonopane

  3. Department of Experimental Medicine, University of L'Aquila, L'Aquila, Italy

    C Festuccia

  4. Department of Radiotherapy Oncology, Sant' Andrea Hospital, University ‘La Sapienza’, L'Aquila, Italy

    P Franzese, M Valeriani & R Maurizi Enrici

Authors
  1. V Tombolini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Di Staso
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P Bonfili
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Di Genesio Pagliuca
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Franzese
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Buonopane
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Valeriani
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R Maurizi Enrici
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C Festuccia
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G L Gravina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G L Gravina.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tombolini, V., Di Staso, M., Bonfili, P. et al. Subjective and objective measures of late genitourinary morbidity following hypofractionated radiotherapy in men with prostate cancer. Prostate Cancer Prostatic Dis 13, 34–38 (2010). https://doi.org/10.1038/pcan.2009.23

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2009.23

Keywords

This article is cited by

Search

Advanced search

Quick links